Interferons Market

The Interferons Market is valued at USD 10.72 Bn in 2026 and is projected to reach USD 13.8 Bn, growing at a CAGR of 4% by 2033.

Ascending Prevalence of Multiple Sclerosis Worldwide Will Contribute Toward Interferons Market Growth

Interferons function in various ways, including immunological control, antiviral actions, and cell development inhibition. The ability of interferons to replicate viral genomes and protect cells from viral infections is quite high. These benefits are boosting demand for interferons. The global interferons market is also anticipated to grow due to interferons' antiviral activities, which include immunoregulatory, anti-angiogenic, and cell growth inhibition. Due to the increased incidence of chronic diseases such as hepatitis B, hepatitis C, cancers, and multiple sclerosis, the global market for interferons is anticipated to expand quickly in the coming years. Interferons can be combined with other medications for hepatitis C, hepatitis B, and cancer treatment, and even in multiple sclerosis (MS) therapeutics with tremendous success because of the utilization of combination therapy and the development of New Drug Delivery Systems (NDDS). For instance, Interferon-alpha in combination with ribavirin and polyethylene glycol molecule has shown significant antiviral properties without side effects, according to the study published in September 2021, titled, ‘The role of type I interferon in the treatment of COVID-19’. The World Health Organization (WHO) estimates that 296 million people worldwide had chronic hepatitis B infections in April 2020, with 1.5 million new infections occurring annually. The estimated global prevalence of multiple sclerosis (MS) will rise to 2.8 million by 2020. As a result, there was a large market for interferons due to the high and rising prevalence rate of these infectious diseases.

Interferons Market: COVID-19 Impact

The interferon market is anticipated to expand due to the coronavirus pandemic epidemic. There are no reliable treatments or vaccinations to prevent this coronavirus infection. To find new COVID-19 therapeutic agents, researchers are screening compound libraries for existing drugs that might have antiviral effects on COVID-19 and creating brand-new drugs that specifically target SARS-CoV-2 or host factors. Trials are being conducted to create viable drug candidates to treat COVID-19 infection effectively. This is one of the elements that will support interferons market expansion soon. For instance, the University of Southampton and Synairgen Research Ltd. reported in July 2020 that SNG001, an inhalation formulation of interferon-beta-1a, is currently being tested in Phase II clinical trials for people with chronic obstructive pulmonary disease (COPD).

Interferons Market Benefits from High Levels of Strategic Cooperation Among Participants

It is anticipated that growth will increase due to the increasing number of interferon-beta approvals by agencies like the Health Research Authority (HRA) and the Medicines and Healthcare Products Regulatory Agency (MHRA). For instance, the interferon-beta-1a inhalation formulation SNG001 is nebulized straight into the lungs. This accelerates market expansion. Major players also increase their visibility through numerous promotions, greater customer services linked to their products, and improved distribution networks to boost the brand and products. For instance, in March 2020, Bayer and Curadev agreed to a license arrangement and research partnership to produce novel STING antagonists for various applications. In auto-inflammatory illnesses, the innate immune system is known to be activated. As a result, the interferons market is growing faster.

Growing Healthcare Awareness to Drive Interferons Market Growth

People are becoming more health conscious, so medications are expected to help the market grow. It is anticipated that the market will be stimulated simultaneously by novel drug introductions to treat squamous cell carcinoma. The development of pharmaceuticals that will benefit the market is funded by many researchers, expanding the market's window of opportunity. Major market players now have a new chance to assess biosimilar clinical applications due to the rising prevalence of cancer, hepatitis, and multiple sclerosis. Many pharmaceutical companies are producing interferon biosimilar medicines to compete with or replace the original products. The global interferons market is expanding due to numerous factors, including rising R&D expenditures and ongoing technical improvements.

Lack of Skilled Professionals Coupled with High Costs Restricts Interferons Market Growth

The development of the worldwide interferons market over the forecast period may be constrained by a lack of qualified specialists who are ignorant of the available treatment options for this illness. Additionally, the high cost of treatment options restrains market expansion. Interferons require more money to develop than tiny molecules made from chemicals. Furthermore, it has higher running costs and demands a bigger capital outlay. Biologic drugs are believed to be more complex than small molecules, necessitating high-quality production methods.

Interferon Beta to Dominate Market Due to Increase in Cases of Multiple Sclerosis (M.S.)

Based on product, the interferons market is segmented into interferon gamma, interferon beta, and interferon alpha. The interferon beta held the largest market share in 2021 and is anticipated to increase significantly over the next several years. Multiple sclerosis is treated with interferon beta medications (M.S.). The CNS, which includes the brain and spinal cord, is afflicted by multiple sclerosis. One of the variables influencing the interferon market is the growing emphasis on creating new interferon beta. For instance, in February 2021, Biogen Inc. received FDA approval for PLEGRIDY (peginterferon beta-1a), a new intramuscular (I.M.) injection route of administration for the treatment of multiple sclerosis. The interferon-beta market is also anticipated to grow as multiple sclerosis (M.S.) becomes more common.

Hospital Pharmacies Category to Dominate Interferons Market, Presence of Trained Physicians Catalyst to Segment’s Growth

Based on end users, the interferons market is segmented into hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies. The phenotypic methods category dominated the market over the forecast period. Without a prescription, interferons are a drug that is well-tolerated and can be used. They have fewer side effects than other medications and can be used for a longer time at lower dosages. They have a high therapeutic index and little chance of having negative consequences. Hospital pharmacies employ interferon treatment (IFNs) to treat liver cancer. Globally, IFN-based therapy is used to treat between 75 and 80 percent of cases, substantially impacting the management of hepatocellular carcinoma or liver cancer. Furthermore, the presence of a qualified physician is necessary for the administration of several medicines. Therefore, it is anticipated that sales and consumer uptake of medicinal substances in a hospital setting will increase.

North America to Dominate Interferons Market Banking on Sophisticated Medical and Healthcare Infrastructure

Over the forecast period, it is anticipated that the North American market will account for the largest revenue share due to the region's sophisticated medical and healthcare infrastructure, availability of professionals, and increased awareness of such cutting-edge treatment techniques among its population. One of the biggest variables that will promote growth in the U.S. is the rising incidence of hepatitis and cancer. According to the Centers for Disease Control and Prevention (CDC), approximately 1,752,735 new cancer cases were recorded in the United States in 2019, and 599,589 cancer-related deaths. Therefore, increased government funding for healthcare facilities is anticipated to fuel R&D efforts in the United States for the introduction of novel interferons. Additionally, the market's expansion in the United States is supported by the presence of key market players, expanding awareness campaigns, and introducing cutting-edge products in the area.

The Asia Pacific interferons market is anticipated to experience stable revenue growth throughout the forecast period, mostly because there are more generic medicines and more government awareness campaigns. The rise in HCV instances in the nation discovered due to ongoing clinical trials on various pharmacological options, including interferons, is also attributable to the growth. Furthermore, over the next few years, market expansion in China is projected to be fueled by rising healthcare costs and the rapid development of medical infrastructure. Additionally, the main reason for the growth is that patients are becoming increasingly aware of the availability of cutting-edge therapy choices like interferons. The Indian market is anticipated to be driven by the development of relatively inexpensive interferon-gamma release assays for latent tuberculosis infection screening. The use of these assays is expected to spread widely in India's low- and middle-income regions.

Global Interferons Market: Competitive Landscape

In December 2021, Biogen and TheraPanacea recently signed a new collaboration agreement to advance digital health for personalized medicine in neuroscience. Similarly, in May 2021, the Novartis subsidiary Sandoz announced that it was increasing its production capacity in Europe to support the establishment of a factory for antibiotics there.

A few of the players in the interferons market include:

• Merck & Co., Inc.
• Biogen Inc.
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited
• Amega Biotech
• PharmaEssentia Corporation
• 3SBio Inc. 

The Global Interferons Market is Segmented as Below:

By Product Type
• Interferon Alpha
• Interferon Beta
• Interferon Gamma

By Application
• Viral Infections (Hepatitis B & C)
• Oncology (Cancer Treatment)
• Multiple Sclerosis
• Others

By Route of Administration
• Injectable
• Intravenous

By End User
• Hospitals
• Specialty Clinics
• Research Institutes

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa